Value, Affordability, and Decision Making
Efficient decisions about allocating health care budgets require assessment of the effects of health care interventions and the value for money they provide. Decision-making processes leading to funding decisions should be structured and evidence-based.
New Publication: Advanced Therapy Medicinal Products and Health Technology Assessment
12 October 2018
A new publication in the European Journal of Health Economics identifies potential challenges of ATMPs in view of current health technology assessment (HTA) methodology and explores…
OHE Lunchtime Seminars: Steven Pearson and Janel Hanmer
4 October 2018
OHE will be hosting two lunchtime seminars in October – one on the 22nd with Steven Pearson, ICER, and another on the 31st with Janel Hanmer,…
MoCA Initiative and its Value Framework: An Opportunity to Improve Decision Making for Orphan Drugs in Europe?
18 September 2018
Orphan drugs inherently face a number of challenges in their development and value assessment. In this blog post, we describe the Mechanism of Coordinated Action (MoCA)…
OHE Lunchtime Seminar: The People’s Prescription – Re-imagining Health Innovation to Deliver Public Value
7 September 2018
OHE Lunchtime Seminar with Mariana Mazzucato on Re-imagining Health Innovation to Deliver Public Value. 28 September 2018 12:00-2:00pm.
UKRI Funds OHE Collaboration in Student Mental Health Research Network
6 September 2018
UK Research and Innovation has awarded OHE a grant as a partner in a national research network for student mental health.
Measuring UK Medicines Expenditure in the Context of the 2014-18 PPRS
29 August 2018
OHE Consulting produces a report on Measuring UK Medicines Expenditure in the Context of the 2014-18 PPRS.
NICE Recommendation Highlights Role of Social Value Judgements
9 August 2018
This blog post discusses the role of social value judgements in NICE technology appraisals, focusing on the recent appraisal of dinutuximab beta for high-risk neuroblastoma.
Opportunity Costs of New Health Care Technologies: A Research Agenda
8 August 2018
A new OHE Research Paper sets out an agenda for the development of methods to estimate cost-effectiveness thresholds in the NHS.
Incentives, Competition, and Pharmaceutical Innovation in Europe: The Case of Direct Acting Antivirals for Hepatitis C
26 July 2018
To what extent can R&D incentives, competition and other factors facilitate access to highly valuable and costly pharmaceutical innovations?